Trial Profile
A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-105 in Patients With Advanced Solid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs ICP 105 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors InnoCare Pharma
- 05 Jul 2022 Status changed from recruiting to completed.
- 28 Jul 2021 Planned End Date changed from 1 Jul 2021 to 31 Dec 2022.
- 28 Jul 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2022.